Researchers sought to determine whether ixazomib added to continuous lenalidomide-dexamethasone would extend PFS in patients with newly diagnosed multiple myeloma.
A progression-free survival benefit did not translate to overall survival.
Researchers sought to determine whether translocation (11;14) and CCND1 affect the likelihood of response to venetoclax in patients with multiple myeloma.
Researchers sought to determine whether subcutaneous daratumumab would require less HCP time and would be a more efficient method for administering the drug.
The results point to patients who might benefit from early intervention.
Overall survival data were not mature.
Researchers sought to determine whether treatment with dose/schedule-adjusted Rd would have similar survival outcomes seen with continuous Rd therapy in patients with multiple myeloma.
Researchers sought to determine whether combination therapies with carfilzomib would be feasible for patients with relapsed/refractory multiple myeloma.
Adding isatuximab to carfilzomib and dexamethasone improved outcomes.
Researchers sought to determine if knowing treatment assignment would lead to patient bias among participants in multiple myeloma clinical trials.
